Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study

Authors: Sally Jane O’Shea, Zoe Rogers, Fiona Warburton, Amanda J. Ramirez, Julia A. Newton-Bishop, Lindsay J. L. Forbes

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The incidence of melanoma is rising. Early detection is associated with a more favourable outcome. The factors that influence the timing of a patient’s presentation for medical assessment are not fully understood.
The aims of the study were to measure the nature and duration of melanoma symptoms in a group of patients diagnosed with melanoma within the preceding 18 months and to identify the symptoms and barriers associated with a delay in presentation.

Methods

A questionnaire was distributed to a random sample of 200 of the 963 melanoma patients who had participated in the Cancer Patient Experience Survey 2010 and were known to be alive 1 year later. Data were collected on symptoms, duration of symptoms prior to presentation and the reasons for not attending a doctor sooner.

Results

A total of 159 patients responded to the questionnaire; 74 (47%) were men; mean age was 62 (range 24–90) years. Of the 149 patients who reported a symptom, 40 (27%) had a delayed presentation (i.e. >3 months). A mole growing bigger was the most common symptom and reporting this symptom was significantly associated with a delayed presentation (odds ratio (OR) 2.04, 95% confidence interval (95% CI) 1.14–5.08). Patients aged ≥65 years were less likely to report a barrier to presentation and were less likely to delay than those under 40, although this was of borderline statistical significance (OR 0.28, 95% CI 0.08–1.00).

Conclusions

This study highlights that an enlarging mole is a significant symptom influencing the timing of presentation. Increasing public awareness of the signs of melanoma and of the importance of early presentation is desirable. Health professionals should take advantage of the opportunity to educate patients on such symptoms and signs where feasible. Further exploration of the barriers to presentation in younger people should be considered.
Appendix
Available only for authorised users
Literature
3.
go back to reference Richard MA, et al. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer. 2000;89(3):271–9.CrossRefPubMed Richard MA, et al. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer. 2000;89(3):271–9.CrossRefPubMed
5.
go back to reference Hansen RP, et al. Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv Res. 2011;11:284.CrossRefPubMedPubMedCentral Hansen RP, et al. Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv Res. 2011;11:284.CrossRefPubMedPubMedCentral
6.
go back to reference Keeble S, et al. Variation in promptness of presentation among 10,297 patients subsequently diagnosed with one of 18 cancers: evidence from a National Audit of Cancer Diagnosis in Primary Care. Int J Cancer. 2014;135(5):1220–8.CrossRefPubMedPubMedCentral Keeble S, et al. Variation in promptness of presentation among 10,297 patients subsequently diagnosed with one of 18 cancers: evidence from a National Audit of Cancer Diagnosis in Primary Care. Int J Cancer. 2014;135(5):1220–8.CrossRefPubMedPubMedCentral
7.
go back to reference Lyratzopoulos G, et al. The relative length of the patient and the primary care interval in patients with 28 common and rarer cancers. Br J Cancer. 2015;112 Suppl 1:S35–40.CrossRefPubMedPubMedCentral Lyratzopoulos G, et al. The relative length of the patient and the primary care interval in patients with 28 common and rarer cancers. Br J Cancer. 2015;112 Suppl 1:S35–40.CrossRefPubMedPubMedCentral
8.
go back to reference Walter FM, et al. ‘This isn’t what mine looked like’: a qualitative study of symptom appraisal and help seeking in people recently diagnosed with melanoma. BMJ Open. 2014;4(7):e005566.CrossRefPubMedPubMedCentral Walter FM, et al. ‘This isn’t what mine looked like’: a qualitative study of symptom appraisal and help seeking in people recently diagnosed with melanoma. BMJ Open. 2014;4(7):e005566.CrossRefPubMedPubMedCentral
9.
go back to reference Simon AE, et al. Patient delay in presentation of possible cancer symptoms: the contribution of knowledge and attitudes in a population sample from the United kingdom. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2272–7.CrossRefPubMedPubMedCentral Simon AE, et al. Patient delay in presentation of possible cancer symptoms: the contribution of knowledge and attitudes in a population sample from the United kingdom. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2272–7.CrossRefPubMedPubMedCentral
10.
go back to reference Nyawata ID, Topping A. Symptom interpretation as a source of delay in malignant melanoma presentation - A literature review. Clin Eff Nurs. 2006;9(s1):e68–78.CrossRef Nyawata ID, Topping A. Symptom interpretation as a source of delay in malignant melanoma presentation - A literature review. Clin Eff Nurs. 2006;9(s1):e68–78.CrossRef
11.
go back to reference Topping A, Nkosana-Nyawata I, Heyman B. ‘I am not someone who gets skin cancer’: risk, time and malignant melanoma. Health Risk Soc. 2013;15(6–7):596–614.CrossRef Topping A, Nkosana-Nyawata I, Heyman B. ‘I am not someone who gets skin cancer’: risk, time and malignant melanoma. Health Risk Soc. 2013;15(6–7):596–614.CrossRef
12.
go back to reference Walter FM, et al. Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study. BMC Fam Pract. 2010;11:62.CrossRefPubMedPubMedCentral Walter FM, et al. Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study. BMC Fam Pract. 2010;11:62.CrossRefPubMedPubMedCentral
13.
go back to reference Whitaker KL, et al. Help seeking for cancer ‘alarm’ symptoms: a qualitative interview study of primary care patients in the UK. Br J Gen Pract. 2015;65(631):e96–e105.CrossRefPubMedPubMedCentral Whitaker KL, et al. Help seeking for cancer ‘alarm’ symptoms: a qualitative interview study of primary care patients in the UK. Br J Gen Pract. 2015;65(631):e96–e105.CrossRefPubMedPubMedCentral
15.
go back to reference Department of Health. National cancer patient experience survey programme: 2010 national survey report. London: Department of Health; 2010. Department of Health. National cancer patient experience survey programme: 2010 national survey report. London: Department of Health; 2010.
18.
go back to reference Newton Bishop JA, Bishop DT. The genetics of susceptibility to cutaneous melanoma. Drugs Today (Barc). 2005;41(3):193–203.CrossRef Newton Bishop JA, Bishop DT. The genetics of susceptibility to cutaneous melanoma. Drugs Today (Barc). 2005;41(3):193–203.CrossRef
20.
go back to reference Nagore E, et al. Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness. Acta Derm Venereol. 2006;86(1):50–6.PubMed Nagore E, et al. Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness. Acta Derm Venereol. 2006;86(1):50–6.PubMed
22.
go back to reference Betti R, et al. Factors of delay in the diagnosis of melanoma. Eur J Dermatol. 2003;13(2):183–8.PubMed Betti R, et al. Factors of delay in the diagnosis of melanoma. Eur J Dermatol. 2003;13(2):183–8.PubMed
23.
go back to reference Baade PD, et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol. 2006;142(11):1422–7.CrossRefPubMed Baade PD, et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol. 2006;142(11):1422–7.CrossRefPubMed
24.
go back to reference Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 2012;22(1):1–8.CrossRefPubMedPubMedCentral Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 2012;22(1):1–8.CrossRefPubMedPubMedCentral
25.
go back to reference Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol. 2005;152(4):673–8.CrossRefPubMed Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol. 2005;152(4):673–8.CrossRefPubMed
26.
go back to reference Feng Z, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992–2007. J Cutan Pathol. 2011;38(8):616–24.CrossRefPubMed Feng Z, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992–2007. J Cutan Pathol. 2011;38(8):616–24.CrossRefPubMed
27.
go back to reference Richard MA, et al. Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol. 1999;135(3):269–74.CrossRefPubMed Richard MA, et al. Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol. 1999;135(3):269–74.CrossRefPubMed
28.
go back to reference Temoshok L, et al. The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. J Psychosom Res. 1985;29(2):139–53.CrossRefPubMed Temoshok L, et al. The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. J Psychosom Res. 1985;29(2):139–53.CrossRefPubMed
Metadata
Title
Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study
Authors
Sally Jane O’Shea
Zoe Rogers
Fiona Warburton
Amanda J. Ramirez
Julia A. Newton-Bishop
Lindsay J. L. Forbes
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2978-6

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine